FDA: Cyramza Approval Now Includes Non-Small-Cell Lung CA

Share this content:
FDA: Cyramza Approval Now Includes Non-Small-Cell Lung CA
FDA: Cyramza Approval Now Includes Non-Small-Cell Lung CA

(HealthDay News) -- U.S. Food and Drug Administration approval of the anti-cancer drug Cyramza (ramucirumab) has been expanded to include aggressive non-small-cell lung cancer (NSCLC), the agency said Friday.

Cyramza is designed to block the blood supply that feeds tumors. It's intended for people whose tumors have grown during or after treatment with other drugs.

Cyramza was first approved in April to treat advanced stomach cancer or gastroesophageal junction (GEJ) adenocarcinoma, and approval was widened in November to include advanced gastric or GEJ adenocarcinoma in combination with paclitaxel.

Clinical side effects have included neutropenia, stomatitis, fatigue, severe bleeding, blood clots, raised blood pressure, and impaired wound healing.

Cyramza is marketed by Eli Lilly, based in Indianapolis.

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

AAP: Congress Urged to Act to Prevent Firearm Deaths

AAP: Congress Urged to Act to Prevent Firearm ...

Following latest shooting, pediatricians join call for action to be taken to address firearm deaths, injury

Lung Cancer Incidence Higher for Young Women Than Young Men

Lung Cancer Incidence Higher for Young Women Than ...

Crossover in sex-specific rates among U.S. non-Hispanic whites born since 1965

E-Cigarette Flavoring Agent May Impair Airway Defense System

E-Cigarette Flavoring Agent May Impair Airway Defense System

Flavoring commonly used in e-cigarettes suppresses cilia beat frequency, lasting for 60 minutes